Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.
By Y. Kasahara, R. Tuder, L. Taraseviciene‐Stewart, T. L. Cras, S. Abman, P. Hirth, J. Waltenberger, N. Voelkel. Journal of Clinical Investigation, 2000
1,167 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/77373a7581b13968a93704bd58cf1937c2f7d0b9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Oncology
Citations in the corpus
- Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. (2001, background): “We recently observed that rats treated with the VEGF R2 inhibitor SU5416 develop emphysema, which is preceded by alveolar septal cell death (32).”
- VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. (2006, background): “Peripheral pulmonary arteries are pruned, and an emphysema-like condition develops in rats treated for 3 wk with the VEGFR tyrosine kinase inhibitor SU5416 (34).”
- VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism (2002, background): “However, interference with this loop may, at least in part, be responsible for certain unexpected effects of small-molecule VEGFR kinase inhibitor”
- Mechanisms of disease: pulmonary arterial hypertension (2011, background): “35, 36 However, when VEGFR inhibition is combined with chronic hypoxia in rats, severe pulmo nary hypertension with angioproliferative lesions develops, 37, 38 and when rats with established pulmonary hypertension are treated with VEGF, the disease is aggravated.”
- Mediators of Chronic Obstructive Pulmonary Disease (2004, background): “Apoptosis of type 1 pneumocytes may be contributory to the development of emphysema, and this might be induced by cytotoxic T lymphocytes or by inhibition of vascular-endothelial growth factor receptors (Kasahara et al., 2000; Majo et al., 2001).”